Effects of antisense oligonucleotides targeting k-ras expression in pancreatic-cancer cell-lines.
The K-ras oncogene is activated in more than 75% of pancreatic cancers and represents a compelling target for therapeutic intervention. We have examined the potential of K-ras antisense oligonucleotides in human pancreatic cancer cell lines. Dose-dependent antiproliferative effects are seen, but these do not correlate with reduced K-ras levels in the treated cells. Although patterns of uptake can be altered by treatment with cationic lipids, this does not enhance antiproliferative effects nor reduce K-ras expression. The antisense approach requires considerable development before useful anti-cancer agents can emerge and alternative approaches are needed for K-ras to be a target for genetic intervention therapy for human cancer.